Country for PR: Hong Kong
Contributor: PR Newswire Asia (Hong Kong)
Wednesday, July 20 2022 - 00:35
AsiaNet
Oncoshot Enters Collaboration Agreement With Omico (Australian Genomic Cancer Medicine Centre)
SINGAPORE, July 19, 2022 /PRNewswire-AsiaNet/ –

Oncoshot has just entered into a collaboration agreement with Omico, the 
Australian Genomic Cancer Medicine Centre. The respective parties were 
represented at the event yesterday by Dr Huren Sivaraj, CEO and co-founder of 
Oncoshot, and Prof David Thomas, CEO of Omico and head of Genomic Cancer 
Medicine at the Garvan Institute. The event was witnessed by guests-of-honour 
Dr Shanny Dyer, CEO of ARCS Australia, and Dr Xiaowei Shi VP, Head of APAC 
clinical operations at BeiGene.

As one of the first of its kind in Australia, this collaboration between Omico 
and Oncoshot is regarded as a potential reference model for the rest of the 
Australian healthcare landscape when it comes to data sharing between private 
and public healthcare stakeholders. As Omico is one of Australia's leading 
cancer research networks, this partnership will create opportunities for global 
trial sponsors to leverage real-time aggregated patient insights with biomarker 
data and present Omico and its network of hospitals as preferred site partners 
within the region.

"Omico is excited to establish this partnership with Oncoshot that will enable 
Australian cancer patients greater access to the latest cancer drugs via global 
clinical trials. Cancer drug development has entered a new era, based around 
rational drug design against molecular targets," says Prof Thomas. 
"Personalised treatment appears more effective than the old one-size-fits-all 
approach. Omico believes that clinical trials represent a critical option for 
our patients, especially when standard treatments fail."

Despite its importance for population health planning, basic and clinical 
research and health industry utilisation, access to health data remains 
problematic. The ability to securely engage in health information exchange can 
reinforce the integration and cooperation between public and private healthcare 
stakeholders to allow both sides to reach healthcare goals together. 
Furthermore, extending this data sharing with the research circle can provide 
insights into strategies to better the effectiveness and efficiency of health 
services while evaluating the influence of new health policies and 
interventions.

Oncoshot's federated data system was designed to satisfy these needs, and at 
the same time, observe data protection regulations that ensure data is shared 
safely and securely. Unlike legacy models requiring data transfer to third 
parties, federated networks allow data to be visited, meaning queries and 
algorithms can be sent to and implemented on the often pseudonymized data. 
Specifically for healthcare, federated health data networks can facilitate 
access to sensitive health data and have the potential to allow large cohort 
analysis across healthcare institutions, regional, and national borders.

About Oncoshot

Oncoshot was founded in 2018 by Dr Huren Sivaraj, a medical oncologist, and 
Ruslan Enikeev, a data science engineer. Oncoshot's mission is to help 
oncologists identify cancer clinical trials more efficiently and effectively 
for patients and their caregivers by supporting hospitals and research 
partners. Its current focus is to leverage technology to address the 
inefficiencies of cancer clinical trials. Oncoshot has expanded to Australia 
and India since its inception in Singapore, an act that highlights its 
applicability and success. Learn more at https://www.oncoshot.com/

About Omico

Omico is a Commonwealth-funded, non-profit, national precision oncology network 
of research and treatment centres that facilitates, supports, and promotes 
clinical trials in genomic cancer medicine. Central to this is the use of 
molecular screening for the prevention of cancer. Omico connects leading 
specialists, researchers, government, industry partners and the community. 
Omico intends to improve outcomes for Australians with cancer by accelerating 
the use of precision oncology as a research-led model of care, growing the 
clinical trials industry, and modernising the Australian healthcare system.

Contact: Diane Galistan, Content Lead, diane@oncoshot.com, +65 8144 7719

Source: Oncoshot

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=425657

   Caption: Oncoshot Enters Collaboration Agreement With Omico (Australian 
Genomic Cancer Medicine Centre)